title: Preference for Rituximab Subcutaneous (Sc) and Intravenous (Iv) Among Patients With Cd20+ Non-Hodgkin's Lymphoma (Nhl) Completing the Rasq Measure In Randomized Phase Iii Studies Prefmab and Mabcute.
authors.affiliation: Derriford Hospital, Plymouth, UK.
authors.forename: S
authors.initials: S
authors.lastname: Rule
authors.affiliation: Santa Creu i Sant Pau Hospital, Barcelona, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Briones
authors.affiliation: F. Hoffmann-La Roche Ltd, Basel, Switzerland.
authors.forename: R
authors.initials: R
authors.lastname: Smith
authors.affiliation: Genentech, South San Francisco, CA, USA.
authors.forename: Oklota C
authors.initials: OC
authors.lastname: Theodore
authors.affiliation: F. Hoffmann-La Roche Ltd, Basel, Switzerland.
authors.forename: C A
authors.initials: CA
authors.lastname: Ngoh
authors.affiliation: F. Hoffmann-La Roche Ltd, Basel, Switzerland.
authors.forename: S
authors.initials: S
authors.lastname: Osborne
authors.affiliation: Centro Aziendale di Ematologia, Livorno, Italy.
authors.forename: E
authors.initials: E
authors.lastname: Capochiani
authors.affiliation: University Hospital Giessen and Marburg, Giessen, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Rummel